MIIST: A Regenerative Modality for Gut Barrier Injury
The human body is protected from insult and injury by important mucosal and dermal barriers. Damage to these barriers initiates an innate immune response that can result in hyperimmune cascades and lead to systemic inflammation. Synedgen’s Multivalent Innate Immune Signaling Target (MIIST) platform promotes mucosal and dermal barrier repair and regeneration. By promoting barrier repair and regeneration, MIIST305 modulates secondary immune signaling to manage the cycle of inflammation, infection, and injury.
Our chemical approach has produced a scientifically validated, diversified drug pipeline able to protect the human body’s natural barriers from radiation, chemical, and traumatic damage. MIIST therapeutics:
Our Discovery Process
Synedgen’s glycopolymer discovery process selects targets that have been conserved through millions of years of evolution. We optimize glycopolymer chemistry to design target-specific therapeutics that are selective for disease physiology.